

09-J3000-65

Original Effective Date: 05/15/20

Reviewed: 12/14/22

Revised: 01/01/23

Subject: Oral Oncology Medications

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

[Position Statement](#)

[Billing/Coding](#)

[Reimbursement](#)

[Program Exceptions](#)

[Definitions](#)

[Related Guidelines](#)

[Other](#)

[References](#)

[Updates](#)

DESCRIPTION:

The National Comprehensive Care Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) provide recommendations for the prevention and treatment of approximately 97% of all cancers in the United States. The NCCN categories for recommendations are based on the level of clinical evidence available and the degree of agreement of a voting multidisciplinary panel of cancer experts with regard to the appropriateness of the intervention. The level of evidence depends upon the quality, quantity, and consistency of data from trials and cases. The voting panel considers the efficacy, safety, and toxicity of treatments available.

| NCCN Categories for recommendations | | Voting panel consensus |
|-------------------------------------|---|----------------------------------|
| Category 1 | Based upon high-level evidence; there is uniform NCCN consensus that the intervention is appropriate | At least 85% |
| Category 2A | Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate | At least 85% |
| Category 2B | Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate | At least 50% (but less than 85%) |
| Category 3 | Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate | At least 25% |

In addition categories of evidence, some of the NCCN Guidelines include recommended levels of preference. The categories of preference are intended to guide selection of the optimal treatment when multiple options are available or to address specific clinical circumstances.

NCCN Categories of preference

| | |
|---------------------------------|--|
| Preferred intervention | Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability |
| Other recommended intervention | Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes |
| Useful in certain circumstances | Other interventions that may be used for select patient populations (defined with recommendation) |

This medical coverage guideline (MCG) applies only to oral oncology agents that do not have an existing MCG developed by Florida Blue or a relevant Prime Therapeutics criteria document. For agents with an existing Florida Blue MCG or relevant Prime Therapeutics criteria document, refer to that MCG/document for medical necessity criteria. Additionally, **Table 1** lists specific drugs that should be reviewed using this MCG. This list is not comprehensive.

POSITION STATEMENT:

Comparative Effectiveness

The FDA has deemed the drug(s) or biological product(s) in this coverage policy to be appropriate for self-administration or administration by a caregiver (i.e., not a healthcare professional). Therefore, coverage (i.e., administration) in a provider-administered setting such as an outpatient hospital, ambulatory surgical suite, physician office, or emergency facility is not considered medically necessary.

Initiation of an oral oncology medication **meets the definition of medical necessity** when **ALL** of the following criteria are met:

- I. **ONE** of the following is met:
 - A. Requested oral oncology product is not included in an existing medical coverage guideline developed by Florida Blue (or relevant Prime Therapeutics criteria document)
 - B. Requested product is listed in [Table 1](#)
- II. **ONE** of the following to support clinical use is met:
 - A. **ALL** of the following are met regarding FDA labeling or NCCN Compendium:
 - i. **ONE** of the following (indication and usage):
 - 1. Member is diagnosed with a condition that is consistent with an indication listed in the product’s FDA-approved prescribing information (or package insert) **AND** member meets any additional requirements listed in the “Indications and Usage” section of the FDA-approved prescribing information (or package insert)
 - 2. Indication **AND** usage is recognized in NCCN Drugs and Biologics Compendium as a Category 1 or 2A recommendation (**Table 2**)
 - ii. **ONE** of the following (diagnostic testing[¶]):
 - 1. **ALL** of the following:
 - a. The requested indication requires genetic/specific diagnostic testing per FDA labeling or NCCN Compendium for the requested agent

- b. Genetic/specific diagnostic testing has been completed
 - c. The results of the genetic/specific diagnostic testing indicate therapy with the requested agent is appropriate – documentation must be submitted
 - 2. The requested indication does **NOT** require specific genetic/diagnostic testing per FDA labeling or NCCN Compendium
 - B. Requested product is designated as an orphan drug by the FDA for the requested indication **AND** the indication is not included in the FDA labeling or the NCCN compendium as a 1 or 2A recommendation (i.e., “Designated/Approved”, “Designated”) (Orphan drug designations can be found at <http://www.accessdata.fda.gov/scripts/opdlisting/oopd/>)
 - C. The indication **AND** usage of the requested product is supported by the results of **TWO or more** published clinical studies – prescriber must submit full text copies of each article
- NOTE:**
- Case reports, posters, and abstracts (including published meeting abstracts) are not accepted as evidence to support for use.
 - Clinical studies must be supportive of use for a similar patient population (e.g., indication, diagnosis, disease severity, genetic or tumor mutations) and for the intended treatment plan, including any concomitant therapy.
- III. The dose does not exceed the maximum FDA-approved dose and frequency with the following exceptions:
- A. Dose and frequency for indication are supported by standard reference compendia (NCCN Compendium or other compendia in **Table 3**)
 - B. Dose and frequency for indication are supported by the results of **TWO** or more published clinical studies – prescriber must submit full text copies of each article
- NOTE:** Dose ranging studies, case reports, posters, and abstracts (including published meeting abstracts) are not accepted as evidence to support use
- IV. The dose will be achieved using the fewest number of capsules or tablets per day
- V. If the requested agent is a brand product with a generic equivalent in the strength requested (noted in **Table 1**) **ALL** of the following are met[†]:
- A. The member has tried and had intolerable adverse effects to the generic product
 - B. The specific intolerance(s) and rationale for using the brand must be specified
 - C. A completed Medwatch reporting form (FDA 3500) must be submitted-
<https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda>
 - D. A completed Naranjo Adverse Drug reaction probability scale must be submitted-
<https://www.floridablue.com/docview/Naranjo-assessment-PDF/>

Approval duration: 6 months (For Vitrakvi, 3 months approval duration)

Continuation of an oral oncology medication **meets the definition of medical necessity** when **ALL** of the following criteria are met:

- I. **ONE** of the following:

- A. Requested oral oncology product is not included in an existing medical coverage guideline developed by Florida Blue (or relevant Prime Therapeutics criteria document)
 - B. Requested product is listed in **Table 1**
- II. The member has been previously approved by Florida Blue or another health plan in the past 2 years for the medication, **OR** the member has previously met all indication-specific criteria for coverage
- III. The dose does not exceed the maximum FDA-approved dose and frequency with the following exceptions:
- A. Dose and frequency for indication are supported by standard reference compendia (NCCN Compendium or **Table 3**)
 - B. Dose and frequency for indication are supported by the results of **TWO** or more published clinical studies – prescriber must submit full text copies of each article
- NOTE:** Dose ranging studies, case reports, posters, and abstracts (including published meeting abstracts) are not accepted as evidence to support use
- IV. The dose will be achieved using the fewest number of capsules or tablets per day
- V. If the requested agent is a brand product with a generic equivalent in the strength requested (noted in **Table 1**) **ALL** of the following are met[†]:
- A. The member has tried and had intolerable adverse effects to the generic product
 - B. The specific intolerance(s) and rationale for using the brand must be specified
 - C. A completed Medwatch reporting form (FDA 3500) must be submitted-
<https://www.fda.gov/safety/medical-product-safety-information/forms-reporting-fda>
 - D. A completed Naranjo Adverse Drug reaction probability scale must be submitted-
<https://www.floridablue.com/docview/Naranjo-assessment-PDF/>

Approval duration: 1 year

[†]Step therapy requirement does not apply if a prior health plan paid for the medication - documentation of a paid claim within the past 90 days must be submitted

Table 1

| Oral oncology medications that must meet medical necessity criteria. (NOTE: This is NOT a comprehensive list of all agents that should be reviewed) |
|--|
| Brand (generic) Product |
| Afinitor (everolimus tablet)* |
| Afinitor Disperz (everolimus tablet for oral suspension)* |
| Alecensa (alectinib) |
| Alunbrig (brigatinib) |
| Ayvakit (avapritinib) |
| Balversa (erdafitinib) |
| Braftovi (encorafenib) |
| Brukinsa (zanubrutinib) |
| Cabometyx (cabozantinib tablets) |
| Calquence (acalabrutinib capsules and tablets) |

| |
|----------------------------------|
| Caprelsa (vandetanib) |
| Cometriq (cabozantinib capsules) |
| Copiktra (duvelisib) |
| Cotellic (cobimetinib) |
| Daurismo (glasdegib) |
| Erivedge (vismodegib) |
| Erleada (apalutamide) |
| Exkivity (mobocertinib) |
| Farydak (panobinostat) |
| Fotivda (tivozanib) |
| Gavreto (pralsetinib) |
| Gilotrif (afatinib) |
| Gleevec (imatinib)* |
| Hycamtin (topotecan capsules) |
| Ibrance (palbociclib) |
| Iclusig (ponatinib) |
| Idhifa (enasidenib) |
| Inlyta (axitinib) |
| Inqovi (decitabine;cedazuridine) |
| Iressa (gefitinib) |
| Jakafi (ruxolitinib) |
| Kisqali (ribociclib) |
| Koselugo (selumetinib) |
| Lenvima (lenvatinib) |
| Lonsurf (trifluridine/tipiracil) |
| Lorbrena (lorlatinib) |
| Lumakras (sotorasib) |
| Lynparza (olaparib) |
| Mekinist (trametinib) |
| Mektovi (binimetinib) |
| Nerlynx (neratinib) |
| Nexavar (sorafenib) |
| Nubeqa (darolutamide) |
| Odomzo (sonidegib) |
| Onureg (azacitidine) |
| Pemazyre (pemigatinib) |
| Piqray (alpelisib) |
| Pomalyst (pomalidomide) |
| Qinlock (ripretinib) |
| Retevmo (selpercatinib) |
| Revlimid (lenalidomide) |
| Rozlytrek (entrectinib) |
| Rubraca (rucaparib) |

| |
|----------------------------------|
| Rydapt (midostaurin) |
| Sprycel (dasatinib) |
| Stivarga (regorafenib) |
| Sutent (sunitinib)* |
| Tabrecta (capmatinib) |
| Tafinlar (dabrafenib) |
| Tagrisso (osimertinib) |
| Talzenna (talazoparib) |
| Tarceva (erlotinib)* |
| Targretin (bexarotene capsules)* |
| Tazverik (tazemetostat) |
| Temodar (temozolomide capsules)* |
| Tepmetko (tepotinib) |
| Tibsovo (ivosidenib) |
| Tretinoin capsule |
| Truseltiq (infigratinib) |
| Tukysa (tucatinib) |
| Turalio (pexidartinib) |
| Tykerb (lapatinib)* |
| Ukoniq (umbralisib) |
| Venclexta (venetoclax) |
| Verzenio (abemaciclib) |
| Vitrakvi (larotrectinib) |
| Vizimpro (dacomitinib) |
| Votrient (pazopanib) |
| Welireg (belzutifan) |
| Xalkori (crizotinib) |
| Xeloda (capecitabine)* |
| Xospata (gilteritinib) |
| Xpovio (selinexor) |
| Xtandi (enzalutamide) |
| Zejula (niraparib) |
| Zelboraf (vemurafenib) |
| Zolinza (vorinostat) |
| Zydelig (idelalisib) |
| Zykadia (ceritinib) |
| *Generic |

Table 2

| NCCN Categories of Evidence Consensus | |
|--|--|
| Category 1 | Based upon high-level evidence; there is uniform NCCN consensus that the intervention is appropriate |

| | |
|-------------|---|
| Category 2A | Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate |
| Category 2B | Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate |
| Category 3 | Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate |

Table 3

| Other compendia | |
|---|---|
| Compendium | Covered Uses[†] |
| AHFS-DI | Narrative text is supportive |
| Clinical Pharmacology | Narrative text is supportive |
| Lexicomp | Evidence rating A, B or G |
| Thomson Micromedex DrugDex | Meets requirements for BOTH of the following: <ul style="list-style-type: none"> • Strength of recommendation: Class I (Recommended) or IIa (Recommended, In Most Cases) • Efficacy: Class I (Effective) or IIa (Evidence Favors Efficacy) |
| [†] If covered use criteria are not met, the request should be denied. AHFS-DI, American Hospital Formulary Service Drug Information; For additional information regarding designated compendia, please refer to the “Definitions” section. | |

FDA Companion Diagnostics: <https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools>

For Medicare Part B and Medicare Advantage members, the reviewer shall refer to National and Local Coverage Determinations. National and Local Coverage Determinations can be found at: <http://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>.

REIMBURSEMENT INFORMATION:

Refer to section entitled [POSITION STATEMENT](#).

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Part D: BCBSF has delegated to Prime Therapeutics authority to make coverage determinations for the Medicare Part D services referenced in this guideline.

Medicare Advantage: No National Coverage Determination (NCD) was found at the time of the last guideline review date. The following Local Coverage Determination (LCD) was reviewed on the last guideline revised date: Label and Off-label Coverage of Outpatient Drugs and Biologicals (L33915) located at fcso.com.

DEFINITIONS:

Table 5

| Lexicomp Recommendation Ratings | |
|--|---|
| A | Consistent evidence from well-performed randomized, controlled trials or overwhelming evidence of some other form (eg, results of the introduction of penicillin treatment) to support the off-label use. Further research is unlikely to change confidence in the estimate of benefit. |
| B | Evidence from randomized, controlled trials with important limitations (inconsistent results, methodological flaws, indirect or imprecise), or very strong evidence of some other research design. Further research (if performed) is likely to have an impact on confidence in the estimate of benefit and risk and may change the estimate. |
| C | Evidence from observational studies (eg, retrospective case series/reports providing significant impact on patient care), unsystematic clinical experience, or from potentially flawed randomized, controlled trials (eg, when limited options exist for condition). Any estimate of effect is uncertain. |
| G | Use has been substantiated by inclusion in at least one evidence-based or consensus-based clinical practice guideline. |

Table 6

| Thomson Micromedex DrugDex Recommendation Ratings: Strength of Recommendation | | |
|--|----------------------------|---|
| Class I | Recommended | The given test or treatment has been proven to be useful, and should be performed or administered |
| Class IIa | Recommended, in most cases | The given test or treatment is generally considered to be useful, and is indicated in most cases. |
| Class IIb | Recommended in some cases | The given test or treatment may be useful, and is indicated in some, but not most, cases |
| Class III | Not recommended | The given test or treatment is not useful and should be avoided |
| Class Indeterminate | Evidence Inconclusive | |

Table 7

| Thomson Micromedex DrugDex Recommendation Ratings: Efficacy | | |
|--|--------------------------|--|
| Class I | Effective | Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is effective |
| Class IIa | Evidence favors efficacy | Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but the weight of evidence and/or expert opinion favors efficacy. |
| Class IIb | Evidence is inconclusive | Evidence and/or expert opinion is conflicting as to whether a given drug treatment for a specific indication is effective, but |

| | | |
|------------------|-------------|--|
| | | the weight of evidence and/or expert opinion argues against efficacy. |
| Class III | Ineffective | Evidence and/or expert opinion suggests that a given drug treatment for a specific indication is ineffective |

RELATED GUIDELINES:

None

OTHER:

None

REFERENCES:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.;2022. URL www.clinicalpharmacology-ip.com Accessed 11/30/22
2. DailyMed [Internet]. Bethesda (MD): National Library of Medicine; Available from: <http://dailymed.nlm.nih.gov/dailymed/index.cfm/>.
3. Drugs@FDA [Internet]. Silver Spring (MD): US Food and Drug Administration; 2022. Available from:http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name/.
4. Lexicomp. [Internet Database]. Wolters Kluwer Clinical Drug Information, Inc. <https://online.lexi.com>
5. Micromedex® Healthcare Series [Internet Database]. Greenwood Village, Colo: Thomson Healthcare. Updated periodically. Accessed 11/30/22.
6. National Comprehensive Cancer Network. Cancer Guidelines. Cancer Guidelines and Drugs and Biologics Compendium. Accessed 11/30/22.
7. Orphan Drug Designations and Approval [Internet]. Silver Spring (MD): US Food and Drug Administration; 2022 [cited 11/30/22]. Available from: <http://www.accessdata.fda.gov/scripts/opdlisting/opd/index.cfm/>.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Pharmacy Policy Committee on 12/14/22.

GUIDELINE UPDATE INFORMATION:

| | |
|----------|--|
| 05/15/20 | New Medical Coverage Guideline |
| 10/01/20 | Revision to guideline; consisting of adding Koselugo, Qinlock, Pemazyre, Retevmo, Tavegyl, and Tukysa to Table 1. |
| 11/15/20 | Revision to guideline; consisting of adding Gavreto, Onureg, and Inqovi to Table 1. |
| 01/15/21 | Revision to guideline; consisting of updating the position statement and adding Afinitor, Afinitor Disperz, Cabometyx, Cometriq, Gleevec, Hycamtin, Tagretin, Tarceva, Temodar, and Xeloda to Table 1. |

| | |
|----------|---|
| 07/01/21 | Revision to guideline; consisting of adding Fotivda, Tepmetko, and Ukoniq to Table 1. |
| 10/01/21 | Revision to guideline; consisting of adding Lumakras and Truseltiq to Table 1. |
| 01/01/22 | Revision to guideline; consisting of adding Exkivity and Welireg to Table 1 and updating generic use of Sutent. |
| 01/15/22 | Revision to guideline; consisting of updating generic use of Afinitor and Afinitor Disperz. |
| 11/15/22 | Review and revision to guideline; consisting of adding Calquence tablets to Table 1. |
| 01/01/23 | Review and revision to guideline; consisting of adding Kisqali to Table 1. |